Astellas Pharma Inc. (TYO:4503)
Japan
· Delayed Price · Currency is JPY 2,000.00
0.00 (0.00%)
At close: Dec 5, 2025
Astellas Pharma Revenue
Astellas Pharma had revenue of 524.32B JPY in the quarter ending September 30, 2025, with 13.37% growth. This brings the company's revenue in the last twelve months to 2.01T, up 13.24% year-over-year. In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T with 19.25% growth.
Revenue (ttm)
2,006.82B
Revenue Growth
+13.24%
P/S Ratio
1.79
Revenue / Employee
147.09M
Employees
13,643
Market Cap
3,582.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,912.32B | 308.65B | 19.25% |
| Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
| Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
| Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
| Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,213.71B |
| HOYA Corporation | 892.50B |
| Takeda Pharmaceutical Company | 4,417.00B |
| Daiichi Sankyo Company | 1,978.88B |
| Otsuka Holdings | 2,418.53B |
| Terumo | 1,062.42B |
| Shionogi & | 437.26B |
| Olympus | 977.65B |
Astellas Pharma News
- 5 days ago - EMA Validates Review Of Astellas' PADCEV And KEYTRUDA Combination In Bladder Cancer - Nasdaq
- 14 days ago - Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 4 weeks ago - Q2 2026 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - Full Year 2025 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 6 weeks ago - Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA) - PRNewsWire
- 6 weeks ago - Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study - Nasdaq
- 6 weeks ago - Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study - PRNewsWire
- 6 weeks ago - PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer - Benzinga